Journal: Haematologica
This interim analysis from the RODEO study examines patient-guided tyrosine kinase inhibitor (TKI) dose reduction in chronic phase chronic myeloid leukemia (CML) patients who are in major molecular remission (MMR).
Using a shared decision-making (SDM) approach supported by a decision aid, 148 patients chose to reduce their TKI dose.
At six months, intervention failure—defined as re-escalation of TKI dose due to loss or expected loss of MMR—occurred in only 2.8% of patients.
Patient-reported outcomes showed modest but statistically significant improvements in symptom burden and quality of life.
The SDM process was well received, with low decisional conflict reported.
Key findings:
- Low intervention failure rate (2.8%) at six months
- Improved symptom burden and quality of life
- Positive reception of the shared decision-making process
These results suggest that patient-guided TKI dose reduction is safe and may improve tolerability without compromising disease control at six months.